RT Journal Article
SR Electronic
T1 What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP i7
OP i10
DO 10.1136/bjophthalmol-2013-303844
VO 98
IS Suppl 1
A1 Avery, Robert L
YR 2014
UL http://bjo.bmj.com/content/98/Suppl_1/i7.abstract
AB Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.